Although children deficient in GH grow slowly and those with GH excess grow at an accelerated rate, it has been difficult to relate height or growth velocity to serum GH concentration as measured by conventional RIA-GH in growing children (1, 2). GH has been shown to exist in a variety of forms in the pituitary gland, and many of these forms are secreted (3) . Circulating GH exhibits additional heterogeneity because it is modified in plasma by proteases and binding proteins (3) (4) (5) (6) . Polyclonal RIA-GH recognize some GH forms that lack bioactivity, whereas other isoforms, which are highly bioactive, may not be recognized (7) (8) (9) . Plasma-binding proteins may modulate GH bioactivity (5. 6 ), but they have little effect on GH detection by RIA (10) . The significance of GH isoforms and the interaction of GH with plasma-binding proteins in the pathophysiologic settings of growth disorders is poorly understood in part because methods for the detection of GH isoform heterogeneity are difficult to apply to clinical serum samples. Estimation of serum GH bioactivity has the potential to provide evidence for the presence of differing GH isoforms or GH modification by binding proteins in the circulation. Although RIA-GH measurement is useful for detection of GH deficiencv, the determination of GH bioactivity in serum might enhance our understanding of the role GH isoforms play in the pathophysiologic settings of growth disorders.
Because of the limitations of available GH bioassays, we recently adapted the physiologically relevant GH-induced suppression of glucose use in murine 3T3-F442A cultured adipocytes for use as an assay to measure GH bioactivity in human serum samples (1 1). This assay detects increases of GH bioactivity after endogenous release or exogenous administration of GHreleasing factor and after pharmacologic stimulation of GH release by arginine and insulin ( 1 1). The purpose of this study was to determine whether B-GH concentrations are related to height, the GH-dependent peptides, IGF-I and IGFBP-3, or both (12, 13). Our hypothesis was that B-GH concentrations would bear a greater correlation to IGF-I and IGFBP-3 than would GH determined by conventional RIA. Girls with Turner's syndrome were studied because their gonadal dysgenesis results in low estrogen production (14) , thereby minimizing the potential impact of changing estradiol concentrations on GH secretion, bioactivity. and expression of GH-binding protein ( 15, 16) . Previous studies estimating GH bioactivity by radioreceptor assays suggest that GH bioactivity is similar to that in normally growing girls ( 17, 18) . Also. because IGF-I concentrations are similar to those of normal girls, the endogenous GH in girls with Turner's syndrome is likely to support normal IGF-I production (17) . Thus, this population of girls was likely to serve as a good model to determine whether GH bioactivity in serum determined in a metabolic assay would have a significant correlation with peptides involved in regulation of growth. (22) with a standard considered significant. Combined data are presented as means 5 and a polyclonal anti-GH antibody provided by the National SEM. ( 14) Karyotype --
Hormone and Pituitary Program (National Institute o f Diabetes and Digestive and Kidney Diseases and the University o f Maryland). The assay sensitivity was 0. I pg/L. and the intraassay CV
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was 4%. LH and FSH were determined in duplicate by Delfia ~' /~u r~c~r c~r i~u r~o t~ o/'.~rlldj~ pop~llutiotl. Girls with Turner's synimmunoflurometric assay from Wallac (Gaithersburg. MD). The drome exhibit karyotype differences
(nmol/l.) (mg/l.) may produce significant amounts of estradiol ( 14) . Because estradiol production could potentially increase GH concentration (15), the degree to which our study population produced estradiol was assessed by measurement of estradiol, FSH, and LH in overnight serum pools from each subject (Fig. 1) Table I . To facilitate comparisons between hormone determinations, we grouped subjects by age to reflect the timing of prepubertal, early to mid-pubertal. and late pubertal development in normal girls. Combined data for ages 4-8 (n = 5). 9-12 (n = 12). and 13-16 (n = 8) y are shown in Figure 2 . Height SDS and RIA-GH were not significantly different among the groups. No significant correlations were seen between age and height SDS ( r = 0.228). age and overnight RIA-GH ( r = 0.097). or age and peak-stimulated RIA-GH ( r = 0.047).
The concentrations of IGF-I and IGFBP-3 increased significantly when compared by age group (Fig. 2) or by regression between age and hormone concentration ( r = 0.48 1. p < 0.05; and r = 0.643. p < 0.005. for IGF-I and IGFBP-3. respectively). B-GH increased with age as well ( r = 0.306), but the increase did not achieve significance ( p = 0.1). B-GH concentrations were positively correlated with IGF-I concentrations, but overnight or peak-stimulated RIA-GH concentrations were not ( Table 2 ). The correlation between B-GH and IGFBP-3 concentrations were better than that between RIA-GH and IGFBP-3 concentrations but did not achieve significance. When measured in serum pools. B-GH and RIA-GH concentrations did not have a significant correlation ( r = 0.09 I). Neither B-GH nor overnight RIA-GH concentrations correlated significantly with height SDS ( r = 0.03 1 for B-GH and 0.262 for RIA-GH). Height velocity, when expressed as SDS (24) . also did not correlate significantly with RIA or B-GH (data not shown).
RIA-GH obtained after pharmacologic stimulation decreased with increasing body mass ( r = 0.53. p = 0.01). The correlation between body mass index and mean RIA-GH was not significant ( r = 0.178, p = 0.40). Also. no significant correlation was observed between body mass index and B-GH ( r = 0.138. p = 0.52).
DISCUSSION
Because GH release is episodic (25), random measurements of serum GH do not accurately reflect the GH secretory status. Compared with single G h measurements. the integration of repeated GH measurements over a 12-to 24-h period has served better as a marker of overall GH release and. in some cases. has borne some correlation to height SDS, growth rate. or both ( I . 2). On the basis of our previous study where nocturnal RIA-GH peaks had more B-GH than did troughs ( I I). it is likely that B-GH varies episodically in serum in a manner similar to RIA-GH. To provide an integrated pool of serum on which to estimate B-GH, we combined equal aliquots of each overnight serum sample for an individual patient. The technique of pooling all overnight samples serves to minimize fluctuations of IGF-I and IGFBP-3 as well as reflecting the mean overnight hormone concentrations of GH. LH. and FSH. The LH and FSH determinations made in the pooled sera are similar to those reported previously by Conte 6. t al. (26) on single serum samples in 58 subjects with Turner's syndrome over a span of ages.
Using an integrated approach to measurements of hormone values, we find a significant correlation between B-GH and IGF-I in 25 girls with Turner's syndrome. In contrast. RIA-GH measurements in the overnight serum pools and the peak RIA-GH response after pharmacologic stimulation do not correlate well with IGF-I. The positive correlation between B-GH and IGF-I is not due to assay cross-reactivity with IGF-I or interference by prolactin ( I I). Because GH is known to result in increased IGF-I concentrations in serum (12) and because RIA-GH measures both bioactive and bioinactive forms of GH (3. 8. 9), B-GH measurements may better reflect the bioactivity of secreted GH forms compared with RIA-GH measurements. The fact that B-GH and RIA-GH do not correlate well in this study also suggests that some of the GH detected by RIA is not biologically active or does not serve to increase IGF-I concentrations in serum. However. because IGF-I concentration in serum is also regulated by nutritional state (27) . the possibility exists that IGF-I concentrations reflect a response to GH-induced changes in nutrition or metabolism rather than a direct response to circulating GH. Alternatively, the possibility that GH bioactivity and IGF-I concentrations both increase in parallel in response to some unknown factor(s) cannot be excluded.
The significant correlation between B-GH and IGF-I, combined with the lack of correlation between B-GH. RIA-GH. or IGF-I and height or growth velocity SDS, suggests that although GH is required for growth, stature in girls with Turner's syndrome appears to be relatively independent of circulating GH concentrations. This situation may have occurred. in part. because the height measures made in this study represent one point in time and may be affected by prior hormonal therapies in some of the girls or by parental height. Body weight may also affect apparent GH secretion and serum concentrations. Although some investigators have demonstrated a decrease in GH secretion with advancing age (28) , others indicate that GH secretion in these girls is likely to be normal especially if GH concentrations are normalized to body mass (29. 30) . Body mass increases with age. and increased body mass has been shown to decrease the amount of secreted GH in girls with Turner's syndrome (29. 30 ). In our study as well. the peak RIA-GH concentrations afier pharmacologc stimulation decrease with increasing body mass index.
Zadik c. 1 ul. ( 17) have recently suggested that girls with Turner's syndrome lack tissue sensitivity to GH or IGF-I. However. these girls exhibit an increase in growth rate when treated with esogenous GH (31) . and their tissue fibroblasts appear to respond normally to IGF-I in vitro (32) . Although these data support the hypothesis that girls with Turner's syndrome produce GH isoforms with subtle differences compared with forms found in normally growing children. indirect bioactivity determinations made previously do not support this notion ( 17. 18) . Direct comparisons between bioactivity in girls with Turner's syndrome and normally growing girls using our new GH bioassay may provide additional insights into the presence of GH isoform differences in future studies.
Our study was designed to determine whether measures of B-GH might correlate better with the GH-dependent peptides. IGF-I and IGFBP-3. than do RIA-GH measurements. The fact that B-GH determined in this assay changes with age in a manner similar to the GH-dependent peptides, IGF-I and IGFBP-3. indicates that the assay is likely to be useful in furthering our understanding of the role that variation in the bioactivity of serum GH plays in regulating serum concentrations of IGF-I in physiologic and pathophysiologic settings.
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